Oncotelic Therapeutics (formerly Mateon Therapeutics) announced that it has licensed an intranasal apomorphine formulation from Autotelic, Inc, a newly formed company owned largely by Oncotelic Chairman and CEO, Vuong Trieu. Oncotelic says that it plans to develop AL-101 nasal apomorphine for Parkinson’s disease, erectile dysfunction, and female sexual dysfunction, including hypoactive sexual desire disorder.
Sunovion’s Kynmobi sublingual apomorphine film was approved by the FDA for the treatment of Parkinson’s in 2020, and Supernus Pharmaceuticals’ Apokyn subcutaneous apomorphine has been approved by the FDA for the treatment of Parkinson’s since 2004.
According to the company, AL-101 intranasal apomorphine is ready to advance to Phase 3 clinical development. Trieu commented, “I am pleased with progress among multiple fronts and look forward to updating our shareholders in the coming weeks. With the acquisition of AL-101 we have positioned the company for its next stage of growth through the fast to market 505(b)2 regulatory pathway more appropriate for a company of our size and history.”
Oncotelic Chief Business Officer Saran Saund said, “The acquisition of AL-101 brings in a product with a substantially large market potential for existing and unmet medical needs into the company. With a substantially large number of new patients being diagnosed with PD, PDE5, ED every year and limited therapies available for FSD and HSDD, the company believes that this acquisition has the potential to transform the company.”
Read the Oncotelic Therapeutics press release.
